Streetbeat News

Equity Actions

SAM

The Boston Beer Company has announced the retirement of Dave Burwick as President, CEO, and Board Member. Michael Spillane will take over as President and CEO. This leadership change could impact the company's strategic direction and investor confidence.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:57 pm

BLFY

Blue Foundry Bancorp has announced a new stock buyback program, under which the company plans to repurchase up to 1.2 million shares. This move is part of the company's strategy to enhance shareholder value.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:55 pm

OGEN

Oragenics has announced a proposed public offering. This move is aimed at raising capital, but the specifics of the offering such as size, price, or timing were not disclosed in the announcement.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:53 pm

NTR

Nutrien has received approval from the Toronto Stock Exchange (TSX) for a renewed share repurchase program, allowing the company to buy back shares. This move is part of Nutrien's strategy to return value to its shareholders and potentially increase the stock's value by reducing the number of shares outstanding.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:51 pm

JANX

Janux Therapeutics has announced a proposed public offering of its common stock, aiming to raise $175 million. This move could potentially dilute current shareholders but also provide the company with significant capital for its operations and development projects.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:50 pm

CYTK

Cytokinetics projects 2024 revenue between $3M-$5M, with operating expenses of $420M-$450M and net cash utilization of $390M-$420M. After raising $83M through ATM equity and considering available long-term debt from Royalty Pharma, the company estimates a two-year cash runway.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:49 pm

ADOC

Edoc Acquisition Corp. has announced the postponement of its special meeting of shareholders, which was initially scheduled to discuss a proposed business combination. The delay indicates a potential reassessment or reevaluation of the terms or conditions related to the business combination.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:45 pm

SHC

Sotera Health announced a secondary offering of 25 million shares of its common stock by selling stockholders, including affiliates of Warburg Pincus LLC and GTCR, LLC, along with two management members and one Board of Directors member.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:43 pm

CJJD

China Jo-Jo Drugstores announced a 1-for-20 reverse stock split, effective immediately. This action is typically taken to increase the market price of a company's shares, making them more appealing to investors and potentially in compliance with stock exchange listing requirements.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:41 pm

ICUI

ICU Medical forecasts its FY24 adjusted EPS to be between $4.40 and $5.10, which is below the estimated $5.18. The company anticipates a GAAP net loss of $88 to $71 million and a diluted loss per share of $3.57 to $2.87. Adjusted EBITDA is expected to range from $330 million to $370 million.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:20 pm